Share this article on:


Puthanakit, Thanyawee MD*; Aurpibul, Linda MD*; Sirisanthana, Thira MD*; Sirisanthana, Virat MD

The Pediatric Infectious Disease Journal: March 2009 - Volume 28 - Issue 3 - p 246-248
doi: 10.1097/INF.0b013e31818dd72b
Brief Reports

Twenty-six Thai HIV-infected children, aged 2 years or less were prospectively enrolled to receive non-nucleoside reverse transcription inhibitor-based highly active antiretroviral therapy (HAART). Twenty-two children (85%) had World Health Organization clinical stage 3 or 4. The median baseline CD4 cell percentage and plasma HIV RNA were 17% and 5.9 log 10 copies/mL, respectively. The median age at HAART initiation was 9.8 months (range, 1.5–24.0). One child died. The mean CD4 cell percentages at 24, 48, and 96 weeks of treatment were 26%, 31%, and 37%, respectively. The proportions of children with virologic suppression (<400 copies/mL) at week 24 and 48 were 14/26 (54%) and 19/26 (73%), respectively. Non-nucleoside reverse transcription inhibitor-based HAART is safe and effective in HIV-infected young children in a resource-limited setting.

From the *Research Institute for Health Sciences, and †Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Accepted for publication September 15, 2008.

Supported by the Thailand Research Fund of the Thai Government.

Address for correspondence: Virat Sirisanthana, MD, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand 50200. E-mail:

Highly active antiretroviral therapy (HAART) substantially reduces HIV-related morbidity and mortality in children living in resource-limited settings.1–4 Although several studies in western countries5–7 have documented the efficacy of HAART in infants and young children there have been few studies from developing countries.8,9 The first-line regimen is usually a non-nucleoside reverse transcription inhibitors (NNRTI)-based regimen. The use of this regimen in Thai children aged >2 years had been shown to be safe and effective.10,11 This prospective study aimed to assess the treatment outcomes of NNRTI-based HAART in HIV-infected children ≤2 years of age in Thailand.

Back to Top | Article Outline


From April 2002 through April 2007, HIV-infected young children at the Chiang Mai University Hospital were prospectively enrolled in the study. Eligibility criteria were: (1) ≤2 years of age, (2) documented HIV infection defined as positive HIV DNA PCR in children ≤18 months of age or positive HIV serology in children >18 months of age, and (3) had advanced or severe symptoms (World Health Organization [WHO] clinical stage 3 or 4) or asymptomatic/mild symptoms (WHO clinical stage 1 or 2) plus CD4 cell percentage ≤25%.

The treatment regimen consisted of nevirapine plus 2 nucleoside reverse transcription inhibitors (NRTIs). The study used an adult fixed-dose combination (FDC) tablet (called GPOvir S30) containing 30 mg of stavudine, 150 mg of lamivudine, and 200 mg of nevirapine produced by the Thai Government Pharmaceutical Organization (TGPO), Bangkok, Thailand. The dosage was calculated to deliver a nevirapine dose of 150 to 200 mg/m2 q12 hours. If a child developed severe adverse effects to nevirapine, treatment was switched to efavirenz-based regimen. The dosage of efavirenz (50- and 200-mg capsules; Bristol-Meyers Squibb) was calculated to deliver at least 15 mg/kg/d of efavirenz as recommended for older children. The 2 NRTIs used in the efavirenz-based regimen were stavudine (15- and 30-mg capsules or syrup; TGPO) and lamivudine (150-mg tablets or syrup; TGPO). The dosages of stavudine and lamivudine were calculated as 1 and 4 mg/kg q12 hours, respectively. The method of using divided adult FDC in pediatric patients at our institute has been reported.10

Children were assessed at week 0, 4, 8, 12, and every 12 weeks thereafter. The rate of adherence was defined as the number of doses taken divided by the total number of doses prescribed. Returned medication was counted and caregiver interviewed. Poor adherence was defined as an adherence rate of <95% recorded at any scheduled visit. Weight and height were expressed as weight-for-age and height-for-age z scores. CD4 cell percentages and plasma HIV RNA level were performed at baseline and every 24 weeks thereafter. The study and informed consent form were approved by the research ethics committee of Chiang Mai University.

Back to Top | Article Outline

Statistical Analysis.

Immune recovery was defined as CD4 cell percentage ≥25%. Virologic suppression was defined as plasma HIV RNA level <400 copies/mL. Patients who died or discontinued NNRTI-based treatment regimen were counted as virologic failure. Their subsequent CD4 cell percentage values were assumed to be <25%. Comparison of variables was performed using Student t test or Fisher exact test as appropriate. Data were analyzed with the SPSS version 11.5 (SPSS Inc., Chicago, IL). A 2-sided P value < 0.05 was considered significant.

Back to Top | Article Outline


Twenty-six children met the eligibility criteria. Thirteen (50%) were male. Nineteen (73%), 3 (12%), and 2 (8%) were in WHO clinical stage 4, 3, 2 and 1, respectively. The median age at HAART initiation was 9.8 months (range, 1.5–24.0). The median body weight was 6.7 kg (range, 4.1–11.5). Treatment characteristics are summarized in Table 1. The median baseline plasma HIV RNA was 5.9 log10 copies/mL (range, 3.9–5.9). Thirteen children (50%) had baseline plasma HIV RNA >750,000 (5.9 log10) copies/mL.



Twenty children (77%) had a history of exposure to antiretroviral drugs to prevent mother to child transmission (PMTCT). Four had been exposed to zidovudine and nevirapine (3 mother-infant pairs and 1 infant). Sixteen had received zidovudine only. Six children had an uncertain history of PMTCT. Only 1 child was breast-fed.

Twenty-five children were started on the nevirapine-based regimen. One child was started on the efavirenz-based regimen because of elevated liver enzyme levels at baseline. Of the 25 children on the nevirapine-based regimen, 3 (12%) developed severe adverse reactions to nevirapine within the first 2 weeks. They were subsequently switched to the efavirenz-based regimen.

One 6-month-old infant (4%) died of immune reconstitution syndrome 9 weeks after HAART initiation. The other 25 children had clinical information for at least 48 weeks after initiation of HAART. None developed any AIDS-related events. The mean CD4 cell percentage significantly increased from baseline at week 24 of treatment and thereafter. At week 48 and week 96, 73% (19/26) and 75% (15/20) of children had CD4 cell percentages ≥25%, respectively.

At week 48, 19 (73%) had virologic suppression, 6 children (23%) had virologic failure, and 1 (4%) died. After week 48 there was no additional child with virologic failure. Five of 6 children with virologic failure were found to have poor adherence to the drug regimen compared with 3 in 20 children without failure (P < 0.01). The NNRTI-based regimen was switched to a protease inhibitor-based regimen in 5 children at the median time of 56 weeks (range, 35–96 weeks). One other child was scheduled to switch after further adherence counseling.

Stored plasma samples before HAART initiation of 16 children were available for genotypic resistance assay. None had resistance mutation to NRTIs. Three (20%) had resistance mutation to NNRTI (Y181C in 2, K103N in 1). None of them had confirmed history of nevirapine exposure as a part of PMTCT regimen. All 3 had virologic failure, compared with 2 of 13(13%) of children without resistance mutation (P < 0.01). These 3 children started HAART at the age of 7.6, 10.0, and 11.3 months, respectively.

Back to Top | Article Outline


Our study demonstrated the efficacy of NNRTI-based HAART regimens in children aged 2 years or less. Seventy-three percent of children achieved virologic suppression at week 48. After week 48 there was no additional patient with virologic failure. The median CD4 cell percentage increased from 17% at baseline to 37% at week 96. Seventy-three and 75% of children had immune recovery at week 48 and week 96, respectively.

The mortality of children in our cohort was 4%. It was comparable with the 6% mortality reported from a large multicenter study among HIV-infected children younger than 5 years of age in Africa and Asia.8 In another study from South Africa, the mortality in the group that had criteria for HAART initiation similar to our study was 16%.9 However, in that study HIV infection was diagnosed before 12 weeks of age, whereas the median age of diagnosis was 9.6 months in our study. Infants with severe HIV disease may have died before seeking medical treatment. This might explain the lower mortality in our study.

After HAART initiation the mean weight z scores and height z scores increased significantly to catch up with normal children of the same age and gender by 24 and 72 weeks, respectively. In our study, >70% of children achieved CD4 cell percentage ≥25% at week 72 of treatment, whereas the median CD4 cell percentage at treatment initiation was only 17%. This was comparable with a study from 14 developing countries, where 62% of children under the age of 5 years achieved a CD4 cell percentage >25% at month 12 of treatment with NNRTI-based HAART regimen. Seventy-nine percent of the patients in this study had the baseline CD4 cell percentage <15%.8

Seventy-three percent of our patients achieved viral suppression at week 48 of treatment. This is comparable with that of a Belgian cohort of 17 infants ≤2.5 months of age, where 71% achieved viral suppression at week 48.12 The efficacy in our cohort is better than that from several earlier studies in HIV-infected young children, most of whom received a nelfinavir-based regimen, where only 50% to 59% achieved viral suppression.5–7

There was a concern regarding the efficacy of NNRTI-based regimen among infants previously exposed to nevirapine as part of PMTCT due to resistance mutation.13 In our study, 3 infants had baseline nevirapine resistance. Most of our patients were referred from outlying hospitals where record keeping was suboptimal. Therefore, although there was no history of nevirapine exposure as part of PMTCT in these 3 infants, unrecorded exposure could not be ruled out. All 3 children had poor virologic outcomes.

The rate of severe adverse drug reactions from nevirapine is 12% (3/25 children) in this study. This was higher than the 5% previously reported in older (median, 7.7 years) HIV-infected Thai children.10

Treatment of HIV-infected children in resource-limited settings is difficult. Choices of antiretroviral drugs are limited because of the high cost of some drugs. Pediatric liquid formulations post logistic problems of short expiration date as well as transport and storage difficulty. Even when available, the dosage schedule (eg, 3 syrup formulations, each with different volume which changes as the child grows) may be too complicated for the caregivers. Chiang Mai University was among the pioneer institutes which took the practical approach of prescribing divided adult FDC antiretroviral tablets to these children.10 Because the ratio of drugs in this FDC is fixed and designed for adult dosing, there is a concern for the possibility of under- or over-dosing of 1 component while trying to strictly follow the dosage recommendation of the other component of the FDC.14,15 However, the alternative is to not give any HAART treatment at all. For similar practical reasons, we have used efavirenz to treat our children who have adverse reaction to nevirapine even though it has not yet been licensed for children <3 years of age.

Despite the constraint mentioned above, NNRTI-based HAART in children aged 2 years or less is safe and effective. However, the virologic outcome in subgroups of children who had poor adherence and/or resistance mutation to NNRTI before antiretroviral treatment is poor. Adherence counseling is mandatory and NNRTI-resistance testing before NNRTI-based HAART initiation in Thai infants should be considered.

Back to Top | Article Outline


1.O'Brien DP, Sauvageot D, Zachariah R, et al. In resource-limited setting good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS. 2006;20:1955–1960.
2.Puthanakit T, Aurpibul L, Oberdorfer P, et al. Hospitalization and mortality of HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis. 2007;44:599–604.
3.Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335–1342.
4.Wamalwa DC, Farquhar C, Obimbo EM, et al. Early response to highly active antiretroviral therapy in HIV-1–infected Kenyan children. J Acquir Immune Defic Syndr. 2007;45:311–317.
5.Faye A, Bertone C, Teglas JP, et al. Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants. Pediatr Infect Dis J. 2002;21:518–525.
6.Doerholt K, Duong T, Tookey P, et al. Outcomes for human immunodeficiancy virus-1 infected infants in the United kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J. 2006;25:420–426.
7.Luzuriaga K, Manus M, Mofenson L, et al. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med. 2004;350:2471–2480.
8.O'Brien DP, Sauvageot D, Olson D, et al.; for Medecins Sans Frontieres. Treatment outcomes stratified by baseline immunological status among young infant receiving nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings. Clin Infect Dis. 2007;44:1245–1248.
9.Violari A, Cotton M, Gibb D, et al. Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young HIV-infected infants: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study. In: 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention; July 22–25, 2007; Sydney, Australia.
10.Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's national access to antiretroviral program. Clin Infect Dis. 2005;41:100–107.
11.Puthanakit T, Aurpibul L, Oberdorfer P, et al. Sustained immunologic and virologic efficacy after 4 years of highly active antiretroviral therapy in human immunodeficiency virus-infected children in Thailand. Pediatr Infect Dis J. 2007;26:953–956.
12.Linden DV, Hainaut M, Goetghrbuer T, et al. Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants. Pediatr Infect Dis J. 2007;26:359–361.
13.Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007;356:135–147.
14.Ellis JC, L'homme RF, Ewings FM, et al. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Antivir Ther. 2007;12:253–260.
15.L'homme RF, Kabamba D, Ewings FM, et al. Nevirapine, stavudine, and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS. 2008;22:557–565.

HIV; young children; NNRTI; infants

© 2009 Lippincott Williams & Wilkins, Inc.